Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients

Detalhes bibliográficos
Autor(a) principal: Cavalcante, Francisca Thaís de Sousa
Data de Publicação: 2021
Outros Autores: Lima, Thayana Maria Navarro Ribeiro de, Bezerra , Paula Maria Maracajá, Vieira, Thiago Isidro, Cavalcanti, Yuri Wanderley, Sousa, Simone Alves de
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/22056
Resumo: Objective: To carry out a cost-effectiveness analysis of the most used antineoplastic treatment protocols of acute leukemia in pediatric patients. Methods: Conducted a cost-effectiveness analysis, using the decision tree model, based on the consultation of secondary data from health information systems in Brazil, SIGTAP - SUS. The population consisted of pediatric patients registered in RHC database of INCA, aged 0 to 19 years, showing lymphocytic / lymphoid / lymphoblastic leukemia as a neoplasm basis, in a period from 1997 to 2017. Results: For male patients, bone marrow transplantation (BMT) exhibited a high increase in the ratio as alternatives and demonstrated the least effectiveness. Despite high incremental costs, the treatment performed with Ct associated with BMT (CtMT), showed effectivess much higher than other alternatives, becoming a cost-effective treatment. The association of Ct with radiotherapy (CtRxt) revealed the most effective treatment. For females patients, the treatment performed with CtBMT has shown to be the least cost-effectiveness, along with BMT. In turn, CtRxt provides to be the best cost-effectiveness treatment. Conclusion: The results of this economic analysis revealed better cost-effectiveness for CtRxt and worse cost-effectiveness for BMT, in both sexes. This analysis showed different scenarios according to the patient's gender, in particular, treatment with CtBMT can be an effective therapeutic option for male patients, but not for female patients.
id UNIFEI_f941368697df8a5159eee82be8565e1f
oai_identifier_str oai:ojs.pkp.sfu.ca:article/22056
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients Coste-efectividad de los enfoques terapéuticos para la leucemia linfocítica aguda en pacientes pediátricos Custo-efetividade das abordagens terapêuticas da leucemia linfocítica aguda em pacientes pediátricos Saúde da CriançaLeucemia LinfoideAnálise custo-benefício.Salud del NiñoLeucemia LinfoideAnálisis costo-beneficio.Child HealthLeukemia, LymphoidCost-benefit analysis.Objective: To carry out a cost-effectiveness analysis of the most used antineoplastic treatment protocols of acute leukemia in pediatric patients. Methods: Conducted a cost-effectiveness analysis, using the decision tree model, based on the consultation of secondary data from health information systems in Brazil, SIGTAP - SUS. The population consisted of pediatric patients registered in RHC database of INCA, aged 0 to 19 years, showing lymphocytic / lymphoid / lymphoblastic leukemia as a neoplasm basis, in a period from 1997 to 2017. Results: For male patients, bone marrow transplantation (BMT) exhibited a high increase in the ratio as alternatives and demonstrated the least effectiveness. Despite high incremental costs, the treatment performed with Ct associated with BMT (CtMT), showed effectivess much higher than other alternatives, becoming a cost-effective treatment. The association of Ct with radiotherapy (CtRxt) revealed the most effective treatment. For females patients, the treatment performed with CtBMT has shown to be the least cost-effectiveness, along with BMT. In turn, CtRxt provides to be the best cost-effectiveness treatment. Conclusion: The results of this economic analysis revealed better cost-effectiveness for CtRxt and worse cost-effectiveness for BMT, in both sexes. This analysis showed different scenarios according to the patient's gender, in particular, treatment with CtBMT can be an effective therapeutic option for male patients, but not for female patients.Objetivo: Realizar un análisis de coste-efectividad de los protocolos antineoplásicos más utilizados en el tratamiento de la leucemia aguda en pacientes pediátricos. Métodos: Se realizó un análisis de costo-efectividad, utilizando un modelo de árbol de decisión, basado en la consulta de datos secundarios de los sistemas de información en salud de Brasil, el SIGTAP - SUS. La población estuvo constituida por pacientes pediátricos registrados en la base de datos de la RHC del INCA, de 0 a 19 años, con leucemia linfocítica / linfoide / linfoblástica como neoplasia basal en el período 1997-2017. Resultados: Para los pacientes masculinos, el trasplante de médula ósea (TMO) exhibió un alto costo incremental en comparación con las alternativas y demostró la menor efectividad. El tratamiento realizado con Qt asociado a TMO (QtBMT), aunque con un coste incremental mayor, resultó mucho más efectivo que otras alternativas, volviéndose rentable. La asociación de Qt con radioterapia (QtRxt) resultó ser el tratamiento más rentable. Para las mujeres, el tratamiento realizado con QtTMO demostró ser el menos rentable, junto con el BMT. A su vez, QtRxt demostró ser más rentable en comparación con otras alternativas. Conclusión: Los resultados de este análisis económico revelaron mejor costo-efectividad para QtRxt y peor costo-efectividad para BMT, en ambos sexos. Este análisis mostró diferentes escenarios según el sexo del paciente, en particular, el tratamiento con QtTMO puede ser una opción terapéutica rentable para pacientes masculinos, pero no para pacientes femeninas.Objetivo: Realizar uma análise de custo-efetividade dos protocolos antineoplásicos mais utilizados no tratamento da leucemia aguda em pacientes pediátricos. Métodos: Realizou-se uma análise de custo-efetividade, com uso de modelo de árvore de decisão, a partir da consulta de dados secundários de sistemas de informação em saúde do Brasil, o SIGTAP - SUS. A população foi composta por pacientes pediátricos registrados na base de dados do RHC do INCA, na faixa-etária de 0 a 19 anos, apresentando leucemia linfocítica/linfoide/linfoblástica como neoplasia de base, no período de 1997-2017. Resultados: Para os pacientes do sexo masculino, o transplante de medula óssea (TMO) exibiu um custo incremental alto em relação às alternativas e demonstrou a menor efetividade. O tratamento realizado com Qt associada ao TMO (QtTMO), embora de custo incremental maior, apresentou efetividade muito superior às alternativas, tornando-se custo-efetiva. A associação de Qt com radioterapia (QtRxt) se revelou o tratamento com maior custo-efetividade. Para o sexo feminino, o tratamento realizado com QtTMO se apresentou como o menos custo-efetivo, juntamente com o TMO. Por sua vez, a QtRxt se mostrou com custo-efetividade maior em relação às alternativas. Conclusão: Os resultados desta análise econômica revelaram melhor custo-efetividade para a QtRxt e pior custo-efetividade para a TMO, em ambos os sexos. Essa análise mostrou diferentes cenários de acordo com o sexo do paciente, em particular, o tratamento com QtTMO pode constituir uma opção terapêutica custo-efetiva para os pacientes do sexo masculino, porém não para os do sexo feminino.Research, Society and Development2021-11-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2205610.33448/rsd-v10i14.22056Research, Society and Development; Vol. 10 No. 14; e383101422056Research, Society and Development; Vol. 10 Núm. 14; e383101422056Research, Society and Development; v. 10 n. 14; e3831014220562525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/22056/19695Copyright (c) 2021 Francisca Thaís de Sousa Cavalcante; Thayana Maria Navarro Ribeiro de Lima; Paula Maria Maracajá Bezerra ; Thiago Isidro Vieira; Yuri Wanderley Cavalcanti; Simone Alves de Sousahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCavalcante, Francisca Thaís de SousaLima, Thayana Maria Navarro Ribeiro de Bezerra , Paula Maria MaracajáVieira, Thiago IsidroCavalcanti, Yuri Wanderley Sousa, Simone Alves de2021-12-04T11:48:39Zoai:ojs.pkp.sfu.ca:article/22056Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:41:19.539978Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
Coste-efectividad de los enfoques terapéuticos para la leucemia linfocítica aguda en pacientes pediátricos
Custo-efetividade das abordagens terapêuticas da leucemia linfocítica aguda em pacientes pediátricos
title Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
spellingShingle Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
Cavalcante, Francisca Thaís de Sousa
Saúde da Criança
Leucemia Linfoide
Análise custo-benefício.
Salud del Niño
Leucemia Linfoide
Análisis costo-beneficio.
Child Health
Leukemia, Lymphoid
Cost-benefit analysis.
title_short Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
title_full Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
title_fullStr Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
title_full_unstemmed Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
title_sort Cost-effectiveness of therapeutic approaches to acute lymphocytic leukemia in pediatric patients
author Cavalcante, Francisca Thaís de Sousa
author_facet Cavalcante, Francisca Thaís de Sousa
Lima, Thayana Maria Navarro Ribeiro de
Bezerra , Paula Maria Maracajá
Vieira, Thiago Isidro
Cavalcanti, Yuri Wanderley
Sousa, Simone Alves de
author_role author
author2 Lima, Thayana Maria Navarro Ribeiro de
Bezerra , Paula Maria Maracajá
Vieira, Thiago Isidro
Cavalcanti, Yuri Wanderley
Sousa, Simone Alves de
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Cavalcante, Francisca Thaís de Sousa
Lima, Thayana Maria Navarro Ribeiro de
Bezerra , Paula Maria Maracajá
Vieira, Thiago Isidro
Cavalcanti, Yuri Wanderley
Sousa, Simone Alves de
dc.subject.por.fl_str_mv Saúde da Criança
Leucemia Linfoide
Análise custo-benefício.
Salud del Niño
Leucemia Linfoide
Análisis costo-beneficio.
Child Health
Leukemia, Lymphoid
Cost-benefit analysis.
topic Saúde da Criança
Leucemia Linfoide
Análise custo-benefício.
Salud del Niño
Leucemia Linfoide
Análisis costo-beneficio.
Child Health
Leukemia, Lymphoid
Cost-benefit analysis.
description Objective: To carry out a cost-effectiveness analysis of the most used antineoplastic treatment protocols of acute leukemia in pediatric patients. Methods: Conducted a cost-effectiveness analysis, using the decision tree model, based on the consultation of secondary data from health information systems in Brazil, SIGTAP - SUS. The population consisted of pediatric patients registered in RHC database of INCA, aged 0 to 19 years, showing lymphocytic / lymphoid / lymphoblastic leukemia as a neoplasm basis, in a period from 1997 to 2017. Results: For male patients, bone marrow transplantation (BMT) exhibited a high increase in the ratio as alternatives and demonstrated the least effectiveness. Despite high incremental costs, the treatment performed with Ct associated with BMT (CtMT), showed effectivess much higher than other alternatives, becoming a cost-effective treatment. The association of Ct with radiotherapy (CtRxt) revealed the most effective treatment. For females patients, the treatment performed with CtBMT has shown to be the least cost-effectiveness, along with BMT. In turn, CtRxt provides to be the best cost-effectiveness treatment. Conclusion: The results of this economic analysis revealed better cost-effectiveness for CtRxt and worse cost-effectiveness for BMT, in both sexes. This analysis showed different scenarios according to the patient's gender, in particular, treatment with CtBMT can be an effective therapeutic option for male patients, but not for female patients.
publishDate 2021
dc.date.none.fl_str_mv 2021-11-06
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/22056
10.33448/rsd-v10i14.22056
url https://rsdjournal.org/index.php/rsd/article/view/22056
identifier_str_mv 10.33448/rsd-v10i14.22056
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/22056/19695
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 14; e383101422056
Research, Society and Development; Vol. 10 Núm. 14; e383101422056
Research, Society and Development; v. 10 n. 14; e383101422056
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052790283960320

Registros relacionados